Hydroxychloroquine Toxicity Management: A Literature Review in COVID-19 Era
- PMID: 33623735
- PMCID: PMC7883488
- DOI: 10.4103/JMAU.JMAU_54_20
Hydroxychloroquine Toxicity Management: A Literature Review in COVID-19 Era
Abstract
Background: Hydroxychloroquine (HCQ) has been widely investigated for the treatment of COVID-19. Although it is rare, several case reports of acute toxicity of HCQ due to overdose have been reported during the last two decades. The aim of this review is to summarize the management options of acute HCQ toxicity.
Methods: A literature review that was conducted using an electronic search in the Google Scholar search engine. The inclusion criteria include any patient over 12 years old presenting with HCQ intoxication symptoms from January 1999 to January 2020.
Results: Sixteen cases were found that have the inclusion criteria of this study. Most patients presented with altered mental status, electrocardiogram abnormalities, visual disturbance, and decrease cardiac output. Activated charcoal was the first line of management in nearly two-thirds of patients whereas 93.8% received fluid resuscitation and 81.3% of the patients need at least one type of vasopressor agent. Furthermore, potassium is given for 93.8% of the patient while 75% of the patients need sodium bicarbonate and intubation, lipid emulsion was used in three patients only and 13 patients survived.
Conclusion: The acute HCQ toxicity may result during the treatment period of COVID-19. The most common options can use in this situation include included gastric lavage and decontamination, IV fluid resuscitation, potassium replacement, sodium bicarbonate, intravenous lipid emulsion, and extracorporeal circulation membrane oxygenation. The role of diazepam is not clear but can be used in the significant toxicity while hyperkalemia associated with severe ingestions.
Keywords: Hydroxychloroquine; overdose; toxicity.
Copyright: © 2020 Journal of Microscopy and Ultrastructure.
Conflict of interest statement
There are no conflicts of interest.
References
-
- Administration USF and D. Fact Sheet for Health Care providers: Emergency use Authorization (EUA) of Hydroxychloroquine Sulfate Supplied from the Strategic National Stockpile for Treatment of COVID-19 in Certain Hospitalized Patients. 2020
-
- Kim AY, Bakhsh HT. Coronavirus Disease 2019 (COVID-19): Management in Hospitalized Adults. 2020. [[Last accessed on 2020 Jun 01]]. Available from: https://www. uptodate.com/contents/coronavirus-disease-2019-covid-19-man... .
-
- Murphy LR, Maskell KF, Kmiecik KJ, Shaffer BM. Intravenous lipid emulsion use for severe hydroxychloroquine toxicity. Am J Ther. 2018;25:e273–5. - PubMed
-
- Mongenot F, Gonthier YT, Derderian F, Durand M, Blin D. Traitement d’une intoxication à l’hydroxychloroquine par circulation extracorporelle. In: Annales francaises d’anesthesie et de reanimation. France: Elsevier; 2007. - PubMed
Publication types
LinkOut - more resources
Full Text Sources